Dr. Siegall is the Chairman, CEO, and President of Immunome, Inc. Previously he was CEO of Morphimmune, a privately held biotechnology company focused on developing targeted oncology therapeutics, where he oversaw the successful merger of Morphimmune and Immunome. Since the merger in October 2023, Dr. Siegall has raised $355 million in equity financings for the company.

Over his 25+ year career in the biopharmaceutical industry, Dr. Siegall has helped to envision, develop, and commercialize multiple targeted therapies that are used daily to help improve the lives of cancer patients around the world. These include the ADCs ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin-ejfv), and TIVDAK® (tisotumab vedotin-tftv), and the small molecule TUKYSA® (tucatinib). All four drugs were developed and/or commercialized by Seagen, Inc., which Dr. Siegall co-founded in 1998 and led for nearly 25 years. Pfizer, Inc. acquired Seagen for $43 billion in late 2023.

With a continued passion for helping to improve outcomes and quality of life for cancer patients with unmet medical need, Dr. Siegall is building on and leveraging his expertise to make Immunome a leader in targeted oncology therapeutics innovation.

Prior to Seagen, Dr. Siegall worked in positions of increasing responsibilities at Bristol Myers Squibb and the National Cancer Institute. He is an author on more than 60 peer-reviewed scientific publications and more than a dozen patents and is the recipient of multiple scientific and biopharmaceutical industry awards. Dr. Siegall currently serves as chairman of the board of directors for Tourmaline Bio, Inc. (Nasdaq: TRML) and as a member of the board of directors of Shattuck Labs, Inc. (Nasdaq: STTK). He earned a PhD in Genetics at George Washington University and a B.S. in Zoology at the University of Maryland.

Dr. Jack Higgins is a biotechnology leader with over a decade of experience. He previously spent 11 years at Molecular Templates, Inc., serving in roles of increasing responsibility before being appointed Chief Development Sciences Officer. During his time at Molecular Templates, Dr. Higgins led discovery and development efforts for multiple clinical candidates and co-invented the company’s Engineered Toxin Body (ETB) platform. Dr. Higgins completed a fellowship in tumorimmunology at the National Cancer Institute. He holds a Ph.D. and M.S from the University of Arkansas and a B.S.from Texas A&M University. 

Kinney Horn has over twenty years of experience in life science finance, leadership, operations, and biopharmaceutical Business Development roles, representing over $30B in transactions. Prior to joining Immunome, Mr. Horn was Chief Business Officer of Olema Oncology, where he was part of the team that completed the company’s $85M Series C crossover financing round and $240M IPO. Before Olema, he was an Entrepreneur in Residence at EcoR1 Capital.

Mr. Horn spent 16 years at Genentech, where his transaction experience included leading teams from of up to 50 employees in identifying pre-clinical and clinical stage opportunities, structuring strategic alliances, negotiating and closing deals, and managing contractual relationships. His international experience includes negotiations with European and Asian companies. In addition to corporate transaction responsibilities, he led the annual oncology strategic sourcing process for 13 areas of oncology research and development.

Prior to Roche’s acquisition of Genentech, Mr. Horn worked with early-stage biotechnology companies that Genentech had invested in through GenenFUND, Genentech’s private equity fund; and began his career in various investment banking and venture roles. Mr. Horn has degrees in economics, international affairs and biochemistry from Mary Washington College and Georgetown University.

Prior to joining Immunome, Dr. Lechleider was the Chief Medical Officer at OncoResponse, where he oversaw the development of the company’s proprietary oncology pipeline. Before OncoResponse, Dr. Lechleider served as the Senior Vice President of clinical development for Seagen, where he was responsible for directing the development of the early and late-stage portfolios, including the successful initial licensing of Padcev® for the treatment of previously treated metastatic urothelial cancer.

Dr. Lechleider began his biotech career at MedImmune (an Astra Zeneca company) and went on to positions of increasing responsibility at Human Genome Sciences and Macrogenics before heading development at Seagen. Prior to his career in biotech, Dr. Lechleider held academic positions where he studied basic cellular and molecular biology.

Dr. Lechleider earned his A.B. from Princeton University and his M.D. from the University of Illinois College of Medicine at Chicago before receiving his clinical residency in internal medicine at Beth Israel-Deaconess Medical Center in Boston, and later in medical oncology at the National Cancer Institute (NCI) in Bethesda.

Max Rosett initially joined Immunome in October 2023 at the close of the company’s merger with Morphimmune. He previously served in roles of increasing responsibility as Morphimmune, concluding as Acting Chief Operating Officer. Prior to Morphimmune, Mr. Rosett was a Principal at Research Bridge Partners, a life science investment firm. He has also worked as a software engineer at Google, and he started his career at the Boston Consulting Group, where he served clients in the pharmaceutical industry. Mr. Rosett earned a M.S. in Computer Science from Georgia Institute of Technology and a B.A. in Mathematics from Yale University.

Sandra G. Stoneman is the Chief Legal Officer and General Counsel of Immunome. In this role, Sandra serves as Corporate Secretary to the Board of Directors and leads the legal, corporate governance, and intellectual property functions of the company. Sandra structures, negotiates and documents the company’s collaborations, partnerships, licenses and strategic and financing transactions. She is a seasoned legal advisor, with more than 20 years of experience advising high-growth companies in the life sciences, medical technologies and high-tech sectors. Prior to her role at Immunome, Sandra was an attorney at the law firms of Duane Morris LLP and Dechert, and is a 1997 magna cum laude graduate of Temple University School of Law, where she was an articles editor for the Temple Law Review, and a summa cum laude graduate of the State University of New York at Binghamton. Sandra has received numerous accolades for her transactional work in the life sciences field, including being continuously listed in U.S. News/Best Lawyers, Chambers USA, LMG Life Sciences and IFLR1000, and being named an Influencer of the Law by The Philadelphia Inquirer, a Best of the Bar by The Philadelphia Business Journal and a Top USA Woman Dealmaker by Global M&A Network.

Prior to joining Immunome, Dr. Tsai spent 21 years at Seagen and then Pfizer (following the acquisition of Seagen in December 2023) in positions of increasing responsibility. Most recently, he was the SVP of Technical Development, responsible for end-to-end development of biologics and drug-linker manufacturing processes, analytics, and drug products. Over the past two decades, he led a productive CMC development organization to advance Seagen’s pipeline, including commercialization of its products. Dr. Tsai began his biotech career at Biogen, where he spent seven years optimizing biologics manufacturing processes.

Dr. Tsai earned his M.S. degree and a PhD in Chemical Engineering with a minor in Biology from California Institute of Technology and a B.S. degree from the University of Illinois, Champaign Urbana. 

Roee Shahar brings over two decades of experience to Immunome, including successfully launching and commercializing oncology and hematology products at Seagen, Pfizer and Eli Lilly & Company.

Prior to joining Immunome, Mr. Shahar served as Vice President and Franchise Lead for Pfizer, where he managed the combined hematology portfolio resulting from the December 2023 acquisition of Seagen. Before the acquisition, he served as Vice President and Franchise Lead for Seagen overseeing all commercial activities for hematology (Adcetris®) and cervical cancer (Tivdak®). Mr. Shahar previously served as Marketing Director and Oncology Brand Leader for Eli Lilly & Company with responsibility for the company’s largest oncology brand at the time, Alimta®.

Mr. Shahar earned his B.S. degree from the Kelley School of Business at Indiana University.